CULLINAN THERAPEUTICS, INC.

CGEM ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Balance Sheet
Annual Quarterly

Balance Sheet

Line Item Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024
Assets
Cash & Equivalents $78.6M $75.1M $88.3M $103.3M $72.8M $76.7M $83.0M $102.1M
Accounts Receivable
Inventory
Total Current Assets $342.0M $361.4M $386.8M $342.2M $275.9M $317.8M $414.7M $592.0M
Property, Plant & Equipment $263.0K $342.0K $421.0K $489.0K $569.0K $607.0K $683.0K $760.0K
Goodwill
Intangible Assets (Excl. Goodwill)
Total Assets $363.8M $403.0M $448.4M $484.1M $520.3M $579.7M $621.8M $653.3M
Liabilities
Accounts Payable $3.7M $2.5M $841.0K $1.7M $2.5M $3.4M $1.7M $2.1M
Total Current Liabilities $40.6M $35.2M $37.7M $32.8M $28.1M $27.3M $30.6M $24.2M
Long-Term Debt
Total Liabilities $42.0M $36.8M $39.6M $32.8M $28.2M $27.8M $31.5M $25.4M
Stockholders' Equity
Retained Earnings $-691.5M $-637.8M $-588.1M $-537.4M $-486.8M $-416.7M $-368.2M $-320.6M
Total Stockholders' Equity $321.8M $366.2M $408.7M $451.4M $492.1M $551.8M $590.3M $627.9M
← Newer Page 1 of 3 Older →